This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nitroprusside for Prevention of no-Reflow in Primary Angioplasty

This study has been terminated.
Information provided by:
Soroka University Medical Center Identifier:
First received: August 9, 2005
Last updated: May 24, 2007
Last verified: May 2007
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on heart function. The study is aimed at examining whether nitroprusside, an anti-hypertension medication, given directly into the coronary artery, can improve the blood flow after the removal of the obstruction that caused the infarction.

Condition Intervention Phase
Myocardial Infarction Drug: Nitroprusside Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Intracoronary Nitroprusside for the Prevention of the No-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. A Randomized, Double Blind, Placebo-Controlled Clinical Trial

Resource links provided by NLM:

Further study details as provided by Soroka University Medical Center:

Primary Outcome Measures:
  • The coronary blood flow in the artery undergoing intervention following angioplasty as determined by the corrected Thrombolysis in Myocardial Infarction (TIMI) frame count (CTFC)
  • Proportion of patients with complete ST-segment resolution immediately after percutaneous coronary intervention (PCI)

Secondary Outcome Measures:
  • The proportion of patients with TIMI grade 3 flow after the procedure
  • The proportion of patients with myocardial grade 3 blush after the procedure
  • The proportion of patients with complete ST-segment resolution at 24 hours post intervention
  • The proportion of patients requiring intra-aortic balloon counter-pulsation and its duration of use
  • Length of hospital stay
  • The combined rate of target vessel revascularization, myocardial infarction or death at 180 days

Estimated Enrollment: 100
Study Start Date: January 2003
Estimated Study Completion Date: April 2005
Detailed Description:
Inadequate myocardial tissue perfusion despite successful relief of the culprit occlusion and restoration of epicardial coronary flow for ST-segment elevation acute myocardial infarction (STEMI) results in poor outcome. The investigators hypothesized that nitroprusside (NTP) injected intracoronary immediately before angioplasty might prevent no-reflow and improve vessel flow and myocardial perfusion.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Acute ST elevation myocardial infarction (MI) patients planned for primary PCI
  • Diagnostic angiography demonstrating a TIMI flow grade <3 in the coronary artery before the PCI

Exclusion Criteria:

  • An admission electrocardiogram (ECG) showing complete left bundle branch block or a paced rhythm
  • Systolic blood pressure < 90 mmHg
  • A history of coronary bypass operation
  • A known allergic reaction to nitroprusside
  • Chronic hemodialysis
  • Intravenous drug abuse
  • Pregnancy
  • Rescue intervention after failed thrombolysis
  • Contraindications to aspirin or clopidogrel
  • Need for emergent coronary artery bypass surgery
  • Inability to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00128791

Soroka University Medical Center
Beer-Sheva, Israel, 84101
Sponsors and Collaborators
Soroka University Medical Center
Principal Investigator: Doron Zahger, MD Soroka UMC, Beer-sheva, Israel
  More Information Identifier: NCT00128791     History of Changes
Other Study ID Numbers: sor323102ctil
Study First Received: August 9, 2005
Last Updated: May 24, 2007

Keywords provided by Soroka University Medical Center:
myocardial infarction
nitric oxide
acute myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Antihypertensive Agents
Vasodilator Agents
Nitric Oxide Donors
Molecular Mechanisms of Pharmacological Action processed this record on June 26, 2017